Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.

ABSTRACT:

Background

Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) including abiraterone. The relationship between PTEN loss and docetaxel sensitivity remains uncertain.

Objective

To study the antitumor activity of docetaxel in metastatic CRPC in relation to PTEN and ERG aberrations.

Design setting and participants

Single-centre, retrospective analysis of PTEN loss and ERG expression using a previously described immunohistochemistry (IHC) binary classification system. Patients received docetaxel between January 1, 2006 and July 31, 2016.

Outcome measurements and statistical analysis

Response correlations were a

SUBMITTER: Rescigno P 

PROVIDER: S-EPMC5995869 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature